Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 10, 2012, Pages 6403-6410

  Wakabayashi, Yoshihiro ^a   Usui, Yoshihiko ^a   Okunuki, Yoko ^a   Ueda, Shunichiro ^a   Kimura, Keisuke ^a   Muramatsu, Daisuke ^a   Kezuka, Takeshi ^a   Goto, Hiroshi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; VASCULOTROPIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; DIABETIC RETINOPATHY; EYE AXIS LENGTH; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR GLAUCOMA; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; VITRECTOMY; VITREOUS BODY; VITREOUS HEMORRHAGE; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AQUEOUS HUMOR; DIABETIC RETINOPATHY; FEMALE; GLAUCOMA, NEOVASCULAR; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY; VITREOUS HEMORRHAGE;

EID: 84871904129     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10367     Document Type: Article

References (30)

1. Oshima Y, Shima C, Wakabayashi T, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology. 2009;116:927-938.
2. Ahn J, Woo SJ, Chung H, Park KH. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology. 2011;118:2218-2226.
3. Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology. 2007;114:710-715.
4. Steel DHW, Habib MS, Park S, Hildreth AJ, Owen RI. Entry site neovascularization and vitreous cavity hemorrhage after diabetic retinopathy. The predictive value of inner sclerostomy site ultrasonography. Ophthalmology. 2008;115:525-532.
5. Hershberger VS, Augsburger JJ, Hutchins RK, et al. Fibrovascular ingrowth at sclerotomy sites in vitretomized diabetic eyes with recurrent vitreous hemorrhage. Ultrasound biomicroscopy findings. Ophthalmology. 2004;111:1215-1221.
6. Lahey JM, Francis RR, Kearney JJ. Combining phacoemulsification with pars plana vitrectomy in patients with proliferative diabetic retinopathy. A series of 223 cases. Ophthalmology. 2003;110:1335-1339.
7. Park DH, Shin JP, Kim SY. Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study. Graffes Arch Clin Exp Ophthalmol. 2010;248:641-650.
8. Kadonosono K, Matsumoto S, Uchio E, Sugita M, Akura J, Ohno S. Iris neovascularization after vitrectomy combined with phacoemulsification and intraocular lens implantation for proliferative diabetic retinopathy. Ophthalmic Surg Lasers. 2001;32:19-24.
9. Scuderi JJ, Blumenkranz MS, Blankenship G. Regression of diabetic rubeosis iridis following successful surgical reattachment of the retina by vitrectomy. Retina. 1982;2:193-196.
10. Adamis AP, Miller JW, Bernal M, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994; 118:445-450.
11. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331:1480-1487.
12. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology. 2005;112:806-816.
13. Wakabayashi Y, Usui Y, Okunuki Y, et al. Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. Retina. 2010;30:339-344.
14. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients. A randomized clinical trial. Ophthalmology. 2009;116:1943-1948.
15. Yeung L, Liu L, Wu WC, et al. Reducing the incidence of early postoperative vitreous haemorrhage by preoperative intravitreal bevacizumab in vitrectomy for diabetic tractional retinal detachment. Acta Ophthalmol. 2010;88:635-640.
16. Prager GW, Johannes MB, Steurer S, Mihaly J, Binder BR. Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood. 2004;103:955-962.
17. Funatsu H, Yamashita H, Miura T, Noma H, Nakamura S, Hori S. Risk evaluation of outcome of vitreous surgery based on vitreous levels of cytokines. Eye. 2007;21:377-382.
18. Koutsandrea CN, Apostolopoulos MN, Chatzoulis DZ, Parikakis EA, Theodossiadis GP. Hemostatic effects of SF6 after diabetic vitrectomy for vitreous hemorrhage. Acta Ophthalmol Scand. 2001;79:34-38.
19. Pierro L, Brancato R, Robino X, Lattanzio R, Jansen A, Caroli G. Axial length in patients with diabetes. Retina. 1999;19:401-404.
20. Lim LS, Lamoureux E, Saw SM, Tay WT, Mitchell P, Wong TY. Are myopic eyes less likely to have diabetic retinopathy? Ophthalmology. 2010;117:524-530.
21. Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Ohji M. Negative correlation between aqueous vascular endothelial growth factor levels and axial length. Jpn J Ophthalmol. 2011; 55:401-404.
22. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105:1801-1815.
23. UK Prospective Diabetes Study (UKPDS) Group. Risk of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus. UKPDS 69. Arch Ophthalmol. 2004;122:1631-1640.
24. Brown GC, Ridley M, Hass D, Lucier AC, Sarin LK. Lipemic diabetic retinopathy. Ophthalmology. 1984;91:1490-1495.
25. Klein BEK, Moss SE, Klein R, Surawcz TS. The Wisconsin epidemiologic study of diabetic retinopathy XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology. 1991;98:1261-1265.
26. Wakabayashi Y, Usui Y, Okunuki Y, et al. Increases of vitreous monocyte chemotactic protein-1 and interleukin-8 levels in patients with concurrent hypertension and diabetic retinopathy. Retina. 2011;31:1951-1957.
27. Suzuma I, Hata Y, Clermont A, et al. Cyclic stretch and hypertension induced retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2. Potential mechanisms for exacerbation of diabetic retinopathy by hypertension. Diabetes. 2001;50:444-454.
28. Helbig H, Kellner U, Bornfeld N, Foerster M. Rubeosis iridis after vitrectomy for diabetic retinopathy. Graffes Arch Clin Exp Ophthalmol. 1998;236:730-733.
29. Blankenship G. Preoperative iris rubeosis and diabetic vitrectomy results. Ophthalmology. 1980;87:176-182.
30. Blankenship G, Cortez R, Machemer R. The lens and pars plana vitrectomy for diabetic retinopathy complications. Arch Ophthalmol. 1979;97:323-328.